MYB insufficiency disrupts proteostasis in hematopoietic stem cells leading to age-related neoplasia
The Myb transcription factor plays critical roles in normal and malignant hematopoiesis.  Acquired genetic dysregulation of Myb, which plays a central role in hematopoietic stem cell (HSC) gene regulation, is involved in the etiology of a number of leukemias. Also, inherited non-coding variants of the Myb gene are a factor in susceptibility to many hematological conditions, including myeloproliferative neoplasms (MPN), but the mechanisms by which variations in Myb levels predispose to disease, including age-dependency in disease occurrence, are completely unknown. Here, we address these key points by showing that Myb insufficiency in mice leads in later life to MPN, myelodysplasia, and leukemia, mirroring the age profile of equivalent human diseases. This age-dependence is intrinsic to HSC, involving progressive accumulation of subtle changes. Interestingly, and linking to previous studies showing the importance of proteostasis to the maintenance of normal HSC, we observed altered proteosomal activity in young Myb-insufficient mice and later elevated ribosome activity. We propose that these alterations collectively cause an imbalance in proteostasis, potentially creating a cellular milieu favoring disease initiation by driver mutations.